Company Akeso, Inc.

Equities

9926

KYG0146B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:03 11/07/2025 pm IST			5-day change	1st Jan Change
113.20 ^HKD	+4.52%		-2.50%	+86.49%

03/07	Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports	RE
03/07	Akeso's First Bispecific Adc (Trop2/Nectin4 Adc) Enters Clinical Trials, Strengthening Leadership in 'Io+Adc'2.0 Strategy	CI

Business description: Akeso, Inc.

Akeso Inc is an investment holding company mainly engaged in the research and development, production and commercialization of biopharmaceutical products. The Company is committed to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwide. The Company's products mainly include cadonilimab (PD-1/CTLA-4), Ivonescimab (AK112, PD-1/VEGF), ANNIKO (penpulimab, PD-1), Ebronucimab (AK102, PCSK9) and ebdarokimab (AK101, IL-12/IL-23). The Company's products are principally used to treat tumors, autoimmune diseases, metabolic diseases, as well as neurodegenerative diseases. The Company principally conducts its businesses in Mainland China, the United States and other markets.

Number of employees: 3,035

Sales by Activity: Akeso, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
Research, Development, Production and Sale of Biopharmaceutical Products	-	23Cr	84Cr	452.63Cr	212.39Cr

See all business segments

Geographical breakdown of sales: Akeso, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
Mainland China	-	9.7Cr	84Cr	159.35Cr	187.8Cr
United States of America (USA)	-	13Cr	-	293.15Cr	24Cr
Other Regions	-	-	-	12.03L	22.56L

See all geographic segments

Executive Committee: Akeso, Inc.

Manager	Title	Age	Since
Peng Zhang PRN	Corporate Officer/Principal	49	16/11/2019
Zhongmin Wang PRN	Corporate Officer/Principal	56	16/11/2019
Baiyong Li CTO	Chief Tech/Sci/R&D Officer	57	16/11/2019
Michelle Xia CEO	Chief Executive Officer	58	19/03/2012
Bing Wang DFI	Director of Finance/CFO	48	22/07/2024

See AKESO, INC. governance

Composition of the Board of Directors: Akeso, Inc.

Director	Title	Age	Since
Michelle Xia CHM	Chairman	58	19/03/2012
Baiyong Li BRD	Director/Board Member	57	16/11/2019
Zhongmin Wang BRD	Director/Board Member	56	16/11/2019
Jun Wen Zeng BRD	Director/Board Member	63	-
Yan Xu BRD	Director/Board Member	61	01/04/2020
Bo Tan BRD	Director/Board Member	51	01/04/2020
Peng Zhang BRD	Director/Board Member	49	30/06/2024
Rong Gang Xie BRD	Director/Board Member	39	19/08/2020

Composition of the Board of Directors

Shareholders: Akeso, Inc.

Name	Equities	%	Valuation
Xia Yu Family 6.194 %	5,55,99,042	6.194 %	651 M $
Green Court Capital Management Ltd. 4.806 %	4,31,40,669	4.806 %	505 M $
Li Bai Yong Family 4.762 %	4,27,38,554	4.762 %	501 M $
Shenzhen Capital Group Co., Ltd. 4.685 %	4,20,52,529	4.685 %	493 M $
Zhang Peng Family 3.594 %	3,22,58,065	3.594 %	378 M $

List of AKESO, INC. shareholders

Company details: Akeso, Inc.

Akeso, Inc.

Torch Development Zone No.6 Shennong Road

528437, Zhongshan

http://www.akesobio.com/en/

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
AKESO, INC.	+4.52%	-2.50%	+195.56%	+385.84%	1.29TCr
ARGENX SE	-1.01%	+2.87%	+11.77%	+33.47%	3.44TCr
WUXI APPTEC CO., LTD.	+9.99%	+8.94%	+98.74%	-28.56%	3.08TCr
BIONTECH SE	-0.90%	+2.63%	+33.28%	-32.19%	2.78TCr
INSMED INCORPORATED	+1.57%	+0.39%	+27.46%	+321.37%	1.86TCr
SUMMIT THERAPEUTICS INC.	-3.40%	+1.83%	+188.02%	+2,400.00%	1.86TCr
WUXI BIOLOGICS (CAYMAN) INC.	+3.70%	+1.72%	+139.66%	-65.41%	1.38TCr
GENMAB A/S	-1.18%	+6.12%	-23.36%	-44.81%	1.33TCr
EXELIXIS, INC.	-0.69%	-2.80%	+98.94%	+117.45%	1.22TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.25%	-6.08%	+139.10%	-	989.88Cr
Average	+1.38%	+2.35%	+90.92%	+343.02%	1.92TCr
Weighted average by Cap.	+1.62%	+3.74%	+78.56%	+300.57%